ARCHIVES

Rev/Vel/Dex Response Rate High In Phase I/II Study

This article is from The Cancer Letter archive.

Vol. 31 No. 1 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

Review Group Urges Increased Funding For NCI AIDS Drug Discovery Program

December 3, 1999

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

January 6, 1989

Surgical Oncologists Honor HHS Secretary

March 22, 2002

NCI TO Issue RFA For Gene Therapy Studies; $20 Mil. Se-Aside Ok’d

January 10, 1992

NCI Support Crucial for Israel cancer Studies; Weizmann Top Recipient

June 17, 1977

LAK/IL-2 Therapy Could Halt Kidney Cancer Deaths: DeVita

March 21, 1986